Arrowhead Pharmaceuticals Corp (ARWR) Tops Q2 EPS by 1c, Miss on Revenues
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $80.19 -2.21%
EPS Growth %: +4.8%
Financial Fact:
TOTAL OPERATING EXPENSES: 19.38M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +4.8%
Financial Fact:
TOTAL OPERATING EXPENSES: 19.38M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $650 thousand versus the consensus estimate of $1.85 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- EU approves Arrowhead's plozasiran for rare triglyceride disorder
- BofA lists top 5 themes driving next $1tn in incremental semi sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
